Results for Patients With Schizophrenia Who Transition to PP3M
A high percentage of patients were persistent and adherent to their PP3M treatment.
A high percentage of patients were persistent and adherent to their PP3M treatment.
A significant improvement in depressive symptoms was measured using validated rating scales.
Long-acting injectables should be considered earlier in the treatment of schizophrenia.
Child maltreatment is significantly more prevalent in young individuals who present with UHR symptoms compared with controls.
In bipolar disorder, neurocognitive impairment needs to be considered a therapeutic clinical target to improve psychosocial functioning.
In cases of PTSD in children, reports showed a marked improvement in nightmares when prazosin was prescribed.
Neither bipolar disorder nor lithium treatment was associated with increased cancer incidence.
Long-term valbenazine may be beneficial in managing tardive dyskinesia.
Enlarged self-perceived areas of pain may be perceived as poorer health status by patients, making the emotional burden worse.
Patients matched to their preferred treatment were more likely to complete the trial but not more likely to achieve depression remission.